ClinicalTrials.gg
CompletedNCT02761252SKYUpdated Jul 12, 2019Results posted

Efficacy of Co-administration of Bilastine and Montelukast in Patients With SARC and Asthma

A Phase 4 interventional study of Bilastine 20mg and Montelukast 10mg in Seasonal Allergic Rhinoconjunctivitis and Asthma, sponsored by Menarini International Operations Luxembourg SA. Completed at 32 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-12.

Sponsored by Menarini International Operations Luxembourg SA (part of Menarini Group) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
454
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 90 studies testing montelukast in Asthma — none open to participants now, none under way, none of them phase 3. montelukast · Asthma.

Enrollment
16th of 90
454 · median 86
Started
2016
the only one that year
Phase 4
32 of 90
none open now
Registered
85th of 90
by date

Among the 90 studies testing montelukast in Asthma, this one is the 16th largest by enrollment, is the only one that started in 2016, is one of 32 in phase 4, and was the 85th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 90 studies testing montelukast in Asthma is open now. The open studies under Asthma, anywhere →

About montelukast

montelukast: first FDA approval 1998 (SINGULAIR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 90 studies testing montelukast in Asthma as a file.
02

Study summary

The purpose of this study is to compare concomitant administration of Montelukast and Bilastine to Montelukast and Bilastine monotherapies in patients with SARC and asthma

Read the detailed description

The present study (SKY) was designed to show if once daily oral combination therapy with Montelukast 10 mg and Bilastine 20 mg is superior to monotherapy with Bilastine 20 mg in patients with Seasonal Allergic RhinoConjunctivitis (SARC) and comorbid mild to moderate asthma on total symptom scores (TSS) and if the combination therapy reflects an improvement in quality of life as assessed via the Asthma Quality of Life Questionnaire (AQLQ) over a longer time period when compared to monotherapies with Montelukast 10 mg and Bilastine 20 mg. Mild to moderate asthma was defined according to the criteria of the Global Initiative for Asthma, i.e., GINA criteria 2 and 3 (GINA, 2012). The study population included patients inadequately controlled on inhaled corticosteroids and in whom "as-needed" short acting beta-agonists provided inadequate clinical control.

03

Conditions studied

  • Seasonal Allergic Rhinoconjunctivitis
  • Asthma

Browse trials for

Keywords

  • Bilastine
  • Montelukast
  • total symptom score
  • AQLQ
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged 18 years or older;
  2. Patients with at least 2 years history of SARC prior to the study and mild to moderate asthma (GINA criteria 2 and 3) inadequately controlled on inhaled and in whom "as-needed" short acting beta-agonists provide inadequate clinical control;
  3. Forced expiratory volume at one second () > 70% of the predicted normal value demonstrable at least 6 hours after last short acting β-2 agonist use or 12 hours after last long acting β-2 agonist (LABA) use;
  4. Nasal Symptoms Score (NSS) at baseline ≥ 3. Baseline NSS will be defined as the mean of the 6 last assessments of the patients' diary (3 last days before randomization);
  5. Positive results of skin prick test on at least one seasonal allergen within the last 3 years;
  6. Patients who provided a signed written form;
  7. Patients who are able and willing to complete web-based Patient's Diary;
  8. Patients who agree to maintain consistency in their surroundings throughout the study period;
  9. Women of (WOCBP) including peri-menopausal women who have had a menstrual period within 1 year have to have a negative pregnancy test. Results have to be available until the Visit 2 and negative for the patient to be entered in the study.
  10. WOCBP have to use an effective method of throughout the study period and for 4 weeks after study completion (defined as a method which results in a failure rate of less than 1% per year) such as:

    • combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal)
    • progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)
    • intrauterine device (IUD)
    • intrauterine hormone-releasing system (IUS)
    • bilateral tubal occlusion
    • vasectomised partner (provided that partner is the sole sexual partner of the trial participant and that the vasectomised partner has received medical assessment of the surgical success)
    • sexual abstinence In each case of delayed menstrual period (over one month between menstruations) confirmation of absence of pregnancy is strongly recommended. This recommendation also applies to WOCBP with infrequent or irregular menstrual cycles.

Exclusion criteria

EXCLUSION CRITERIA

  1. Patients with to any component of the study medications;
  2. Patients with non-allergic rhinoconjunctivitis (e.g. vasomotor, infectious, drug-induced);
  3. Presence of nasal polyps or any nasal anomaly;
  4. History of acute and/or chronic sinusitis within 30 days of Visit 2;
  5. History of eye surgery within 3 months of Visit 2;
  6. History of intranasal surgery within 3 months of Visit 2;
  7. Immunotherapy within 6 months prior to Visit 1;
  8. Upper respiratory infections including cold and systemic infections within 3 weeks of Visit 2;
  9. Patients with moderate to severe renal impairment and taking P-gp inhibitors (e.g. ketoconazole, erythromycin, cyclosporine, ritonavir, diltiazem) within 7 days prior to the first dose of study medication;
  10. Patients requiring daily "controller" medications with cromolyn-type drugs or leukotriene antagonists;
  11. Patient required daily "controller" medication with Inhaled (ICS) or LABA at medium /high dosage defined by GINA criteria;
  12. Patients with clinically important (based on principal investigator's judgment) hepatic impairment;
  13. Patients with severe concomitant disease (based on principal investigator's judgment) that could interfere with treatment response;
  14. Patients with syndrome;
  15. Patients with Galactose intolerance, Lapp lactase deficiency or glucose- galactose malabsorption;
  16. Pregnant or breast-feeding women;
  17. Patients with a mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study (based on principal investigator's judgment);
  18. Patients who had a recent history (within previous 12 months) of drug addiction or alcohol abuse based on Principal investigator's judgment ;
  19. Patients participating in or having participated in another clinical trial within the previous three months;
  20. Patients unable to take relief medications due to or intolerance;
  21. Patients who are taking or have taken any of the following medications prior to randomisation in the study and have not complied with the specified :

    • Antihistaminic drugs or montelukast (7 days)
    • Systemic or intranasal corticosteroids (4 weeks)
    • Delayed-release corticosteroids (3 months)
    • Ketotifen (2 weeks)
    • Macrolides antibiotics and imidazolic antifungals (systemic)(7 days)
    • Anticholinergics (7 days)
    • Drugs with antihistamine properties (phenothiazine) (7 days)
    • Intranasal and systemic decongestants (3 days)
    • Lodoxamide (7 days)
  22. Patients who will be operating heavy machinery or need to drive motor vehicles as an essential part of their profession.
  23. Patients who are planning to travel outside the study area during the course of the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
454 participants (actual)

Study arms

  • Experimental
    Bilastine+montelukast

    Bilastine 20 mg, 10 blister containing 10 tablets + Montelukast 10 mg, 10 blister containing 10 film coated tablets each for treatment

    Drug: Bilastine 20mg · Drug: Montelukast 10mg

  • Active comparator
    Bilastine+placebo montelukast

    Bilastine 20 mg, 10 blister containing 10 tablets + Placebo Montelukast, 10 blister containing 10 film coated tablets each.

    Drug: Bilastine 20mg · Drug: Placebo Montelukast 10mg

  • Active comparator
    Montelukast+placebo bilastine

    Placebo Bilastine, 10 blister containing 10 tablets + Montelukast 10 mg, 10 blister containing 10 film coated tablets each.

    Drug: Montelukast 10mg · Drug: Placebo Bilastine 20mg

Interventions

  • Also known as: Robilas

  • Also known as: Montelukast

  • DrugPlacebo Bilastine 20mg

    Also known as: Placebo Bilastine

  • DrugPlacebo Montelukast 10mg

    Also known as: Placebo Montelukast

06

What researchers measure

Primary outcomes

  1. Change From Baseline With Montelukast+Bilastine Compared With Bilastine Monotherapy in SARC Symptoms

    To demonstrate that concomitant administration of montelukast and bilastine is superior to bilastine monotherapy in SARC symptoms, as assessed by Total Symptoms Scores (TSS) after 4 weeks of treatment. Total Symptoms Scores (TSS) assesses nasal (nasal congestion, rhinorrhea, nasal itching, sneezing) and non nasal symptoms (ocular redness, ocular itching, tearing) of rhinoconjuctivits. Each of the 7 symptoms is scored from 0 (absent) to 3 (severe) as follows: * 0 (absent) Symptom not present * 1 (mild) Symptom is clearly present but easily tolerated, a nuisance, minimal awareness * 2 (moderate) Symptom is bothersome but tolerable, does not interfere with daily activities or sleep * 3 (severe) Symptom is hard to tolerate and interferes with daily activities or sleep. TSS assessment comprises of scoring (0-3) of all 7 above mentioned symptoms. Final TSS scores is in a range from 0-21.

    Time frame: 4 weeks of treatment (from baseline to 4 weeks of treatment)

Secondary outcomes

  1. Change From Baseline With Montelukast+Bilastine Compared With Montelukast and Bilastine Monotherapies in Asthma Control

    To evaluate the efficacy of concomitant montelukast and bilastine compared with montelukast and bilastine monotherapies in asthma control, as assessed by Asthma Quality of Life Questionnaire (AQLQ) after 4 weeks. The AQLQ was developed to measure the functional problems (physical, emotional, social and occupational) that are most troublesome to adults (17-70 years) with asthma. Each of the 32 questionnaire's items will be scored on a 7-point scale (where 7 means "not impaired at all" and 1 means "severely impaired"). The overall AQLQ score is the mean of all 32 responses (https://www.qoltech.co.uk/aqlq.html). The change in AQLQ score from baseline to 4 weeks after treatment - AQLQ score at baseline for patients with both available values has been the secondary endpoint.

    Time frame: After 4 weeks of treatments

  2. Change From Baseline With Montelukast+Bilastine Compared With Montelukast and Bilastine Monotherapies in SARC Symptoms (DNSS)

    To evaluate the efficacy of concomitant montelukast and bilastine compared with montelukast and bilastine monotherapies in daytime symptoms of SARC, as assessed by Daytime Nasal Symptom Score (DNSS) after 4 weeks of treatment. Daytime Nasal Symptom Score (DNSS) is the average of individual scores of nasal congestion, rhinorrhea, nasal itching, sneezing of rhinoconjuctivits. Each of the 4 symptoms is scored from 0 (absent) to 3 (severe) as follows: * 0 (absent) Symptom not present * 1 (mild) Symptom is clearly present but easily tolerated, a nuisance, minimal awareness * 2 (moderate) Symptom is bothersome but tolerable, does not interfere with daily activities or sleep * 3 (severe) Symptom is hard to tolerate and interferes with daily activities or sleep. DNSS assessment comprises of scoring (0-3) of all 4 above mentioned symptoms. Final DNSS scores is in a range from 0-12.

    Time frame: After 4 weeks of treatment (from baseline)

  3. Change From Baseline With Montelukast + Bilastine Compared With Montelukast and Bilastine Monotherapies in SARC Symptoms (DNNSS)

    To evaluate the efficacy of concomitant montelukast and bilastine compared with montelukast and bilastine monotherapies in daytime symptoms of SARC, as assessed by Daytime Non Nasal Symptom Score (DNNSS) after 4 weeks of treatment. Daytime Non Nasal Symptom Score (DNSS) is the average of individual scores of ocular redness, ocular itching and tearing of rhinoconjuctivits. Each of the 3 symptoms is scored from 0 (absent) to 3 (severe) as follows: * 0 (absent) Symptom not present * 1 (mild) Symptom is clearly present but easily tolerated, a nuisance, minimal awareness * 2 (moderate) Symptom is bothersome but tolerable, does not interfere with daily activities or sleep * 3 (severe) Symptom is hard to tolerate and interferes with daily activities or sleep. DNNSS assessment comprises of scoring (0-3) of all 3 above mentioned symptoms. Final DNNSS scores is in a range from 0-9.

    Time frame: After 4 weeks of treatment (from baseline)

  4. Usage of Relief Medication for SARC

    Number of days without any relief medication for SARC

    Time frame: From baseline to 4 weeks of treatment

  5. Usage of Relief Medication for Asthma

    Number of days without any relief medication for Asthma.

    Time frame: From baseline to 4 weeks of treatment

07

Results

Posted Jul 12, 2019

Participant flow

The recruitment started on 13 April 2016 and termineted on 23 November 2016. 454 patients with SARC and mild to moderate asthma as comorbidity were screened. 420 patients were randomised of which 388 patients completed the study.

Participant flow — Overall Study
MilestoneBilastine+MontelukastBilastine MonotherapyMontelukast Monotherapy
Started143140137
Completed133132123
Not completed10814

Outcome measures

PrimaryChange From Baseline With Montelukast+Bilastine Compared With Bilastine Monotherapy in SARC Symptoms

To demonstrate that concomitant administration of montelukast and bilastine is superior to bilastine monotherapy in SARC symptoms, as assessed by Total Symptoms Scores (TSS) after 4 weeks of treatment. Total Symptoms Scores (TSS) assesses nasal (nasal congestion, rhinorrhea, nasal itching, sneezing) and non nasal symptoms (ocular redness, ocular itching, tearing) of rhinoconjuctivits. Each of the 7 symptoms is scored from 0 (absent) to 3 (severe) as follows: * 0 (absent) Symptom not present * 1 (mild) Symptom is clearly present but easily tolerated, a nuisance, minimal awareness * 2 (moderate) Symptom is bothersome but tolerable, does not interfere with daily activities or sleep * 3 (severe) Symptom is hard to tolerate and interferes with daily activities or sleep. TSS assessment comprises of scoring (0-3) of all 7 above mentioned symptoms. Final TSS scores is in a range from 0-21.

Time frame:
4 weeks of treatment (from baseline to 4 weeks of treatment)
Reported as:
Mean · score on a scale
Change From Baseline With Montelukast+Bilastine Compared With Bilastine Monotherapy in SARC Symptoms
score on a scaleBilastine+MontelukastBilastine Monotherapy
Change From Baseline With Montelukast+Bilastine Compared With Bilastine Monotherapy in SARC Symptoms-3.2522 (-3.8718 to -2.6327)-3.4462 (-4.0708 to -2.8217)
Statistical analysis
  • Bilastine+Montelukast vs Bilastine Monotherapy · ANCOVA · p = 0.5721 · Mean difference (final values): -0.194 · 95% CI -0.8693 to 0.4813
SecondaryChange From Baseline With Montelukast+Bilastine Compared With Montelukast and Bilastine Monotherapies in Asthma Control

To evaluate the efficacy of concomitant montelukast and bilastine compared with montelukast and bilastine monotherapies in asthma control, as assessed by Asthma Quality of Life Questionnaire (AQLQ) after 4 weeks. The AQLQ was developed to measure the functional problems (physical, emotional, social and occupational) that are most troublesome to adults (17-70 years) with asthma. Each of the 32 questionnaire's items will be scored on a 7-point scale (where 7 means "not impaired at all" and 1 means "severely impaired"). The overall AQLQ score is the mean of all 32 responses (https://www.qoltech.co.uk/aqlq.html). The change in AQLQ score from baseline to 4 weeks after treatment - AQLQ score at baseline for patients with both available values has been the secondary endpoint.

Time frame:
After 4 weeks of treatments
Reported as:
Mean · score on a scale
Change From Baseline With Montelukast+Bilastine Compared With Montelukast and Bilastine Monotherapies in Asthma Control
score on a scaleBilastine+MontelukastBilastine MonotherapyMontelukast Monotherapy
Change From Baseline With Montelukast+Bilastine Compared With Montelukast and Bilastine Monotherapies in Asthma Control0.6250 (0.4788 to 0.7712)0.6399 (0.4929 to 0.7870)0.5849 (0.4344 to 0.7353)
Statistical analysis
  • Bilastine+Montelukast vs Bilastine Monotherapy vs Montelukast Monotherapy · ANCOVA · p = 0.0105 · Mean difference (final values): -1.1552 · 95% CI -2.0379 to -0.2725
SecondaryChange From Baseline With Montelukast+Bilastine Compared With Montelukast and Bilastine Monotherapies in SARC Symptoms (DNSS)

To evaluate the efficacy of concomitant montelukast and bilastine compared with montelukast and bilastine monotherapies in daytime symptoms of SARC, as assessed by Daytime Nasal Symptom Score (DNSS) after 4 weeks of treatment. Daytime Nasal Symptom Score (DNSS) is the average of individual scores of nasal congestion, rhinorrhea, nasal itching, sneezing of rhinoconjuctivits. Each of the 4 symptoms is scored from 0 (absent) to 3 (severe) as follows: * 0 (absent) Symptom not present * 1 (mild) Symptom is clearly present but easily tolerated, a nuisance, minimal awareness * 2 (moderate) Symptom is bothersome but tolerable, does not interfere with daily activities or sleep * 3 (severe) Symptom is hard to tolerate and interferes with daily activities or sleep. DNSS assessment comprises of scoring (0-3) of all 4 above mentioned symptoms. Final DNSS scores is in a range from 0-12.

Time frame:
After 4 weeks of treatment (from baseline)
Reported as:
Mean · score on a scale
Change From Baseline With Montelukast+Bilastine Compared With Montelukast and Bilastine Monotherapies in SARC Symptoms (DNSS)
score on a scaleBilastine+MontelukastBilastine MonotherapyMontelukast Monotherapy
Change From Baseline With Montelukast+Bilastine Compared With Montelukast and Bilastine Monotherapies in SARC Symptoms (DNSS)-1.9713 (-2.3442 to -1.5984)-2.1106 (-2.4863 to -1.7349)-1.8678 (-2.2468 to -1.4888)
Statistical analysis
  • Bilastine+Montelukast vs Bilastine Monotherapy vs Montelukast Monotherapy · ANCOVA · p = 0.4885 · Mean difference (final values): -0.1393 · 95% CI -0.5342 to 0.2557
SecondaryChange From Baseline With Montelukast + Bilastine Compared With Montelukast and Bilastine Monotherapies in SARC Symptoms (DNNSS)

To evaluate the efficacy of concomitant montelukast and bilastine compared with montelukast and bilastine monotherapies in daytime symptoms of SARC, as assessed by Daytime Non Nasal Symptom Score (DNNSS) after 4 weeks of treatment. Daytime Non Nasal Symptom Score (DNSS) is the average of individual scores of ocular redness, ocular itching and tearing of rhinoconjuctivits. Each of the 3 symptoms is scored from 0 (absent) to 3 (severe) as follows: * 0 (absent) Symptom not present * 1 (mild) Symptom is clearly present but easily tolerated, a nuisance, minimal awareness * 2 (moderate) Symptom is bothersome but tolerable, does not interfere with daily activities or sleep * 3 (severe) Symptom is hard to tolerate and interferes with daily activities or sleep. DNNSS assessment comprises of scoring (0-3) of all 3 above mentioned symptoms. Final DNNSS scores is in a range from 0-9.

Time frame:
After 4 weeks of treatment (from baseline)
Reported as:
Mean · score on a scale
Change From Baseline With Montelukast + Bilastine Compared With Montelukast and Bilastine Monotherapies in SARC Symptoms (DNNSS)
score on a scaleBilastine+MontelukastBilastine MonotherapyMontelukast Monotherapy
Change From Baseline With Montelukast + Bilastine Compared With Montelukast and Bilastine Monotherapies in SARC Symptoms (DNNSS)-1.2824 (-1.5667 to -0.9980)-1.3185 (-1.6051 to -1.0320)-1.1574 (-1.4462 to -0.8687)
Statistical analysis
  • Bilastine+Montelukast vs Bilastine Monotherapy vs Montelukast Monotherapy · ANCOVA · p = 0.81032 · Mean difference (final values): -0.03615 · 95% CI -0.3319 to 0.2596
SecondaryUsage of Relief Medication for SARC

Number of days without any relief medication for SARC

Time frame:
From baseline to 4 weeks of treatment
Reported as:
Least squares mean · Days
Usage of Relief Medication for SARC
DaysBilastine+MontelukastBilastine MonotherapyMontelukast Monotherapy
Usage of Relief Medication for SARC15.0057 ± 0.826015.8416 ± 0.832615.4179 ± 0.8411
Statistical analysis
  • Bilastine+Montelukast vs Bilastine Monotherapy vs Montelukast Monotherapy · ANOVA · p = 0.3704 · Mean difference (final values): 0.8359 · 95% CI -0.9969 to 2.6688
SecondaryUsage of Relief Medication for Asthma

Number of days without any relief medication for Asthma.

Time frame:
From baseline to 4 weeks of treatment
Reported as:
Least squares mean · Days
Usage of Relief Medication for Asthma
DaysBilastine+MontelukastBilastine MonotherapyMontelukast Monotherapy
Usage of Relief Medication for Asthma53.2548 ± 2.019352.4177 ± 2.021250.7146 ± 2.0768
Statistical analysis
  • Bilastine+Montelukast vs Bilastine Monotherapy vs Montelukast Monotherapy · ANOVA · p = 0.7452 · Median difference (final values): -0.837 · 95% CI -5.8968 to 4.2228

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bilastine+Montelukast—0/143 (0%)8/143 (5.6%)
Bilastine+Placebo Montelukast—0/140 (0%)4/140 (2.9%)
Montelukast+Placebo Bilastine—1/137 (0.7%)14/137 (10.2%)
Most frequent serious events
Most frequent serious events
EventBilastine+MontelukastBilastine+Placebo MontelukastMontelukast+Placebo Bilastine
Abdominal PainGastrointestinal disorders0/1430/1401/137
Most frequent other events
Showing 10 of 18
Most frequent other events
EventBilastine+MontelukastBilastine+Placebo MontelukastMontelukast+Placebo Bilastine
DizzinessNervous system disorders0/1430/1402/137
SomnolenceNervous system disorders2/1432/1402/137
Alanine Aminotransferase IncreasedInvestigations2/1430/1400/137
Gamma-glutamytrasferase IncreasedInvestigations1/1430/1401/137
HeadacheNervous system disorders1/1430/1401/137
HypoaesthesiaNervous system disorders0/1430/1401/137
SedationNervous system disorders1/1430/1401/137
AnxietyPsychiatric disorders0/1430/1401/137
IrritabilityPsychiatric disorders0/1430/1401/137
Gastrooesophageal Reflux DiseaseGastrointestinal disorders0/1430/1401/137

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Bilastine+MontelukastBilastine MonotherapyMontelukast MonotherapyTotal
<=18 years0000
Between 18 and 65 years143140137420
>=65 years0000
Age, Continuous
Age, Continuous(years)Bilastine+MontelukastBilastine MonotherapyMontelukast MonotherapyTotal
Mean34.9 ± 11.135.5 ± 11.035.4 ± 10.735.2 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)Bilastine+MontelukastBilastine MonotherapyMontelukast MonotherapyTotal
Female698373225
Male745764195
08

Study locations

32 sites
  • Cakovec, Croatia
  • Rijeka, Croatia
  • Zagreb, Croatia
  • Brno, Czechia
  • Ostrava Hrabuvka, Czechia
  • Teplice, Czechia
  • Dreieich, Germany
  • Heidelberg, Germany
  • Catania, Italy
  • Florence, Italy
  • Modena, Italy
  • Pavia, Italy
  • Verona, Italy
  • Riga, Latvia
  • Bialystok, Poland
  • Bielsko-Biala, Poland
  • Gdansk, Poland
  • Katowice, Poland
  • Krakow, Poland
  • Lodz, Poland
  • Lublin, Poland
  • Nowy Duninow, Poland
  • Poznan, Poland
  • Rzeszow, Poland
  • Tarnow, Poland
  • Wroclaw, Poland
  • Brasov, Romania
  • Bucharest, Romania
  • Cluj Napoca, Romania
  • Ploieşti, Romania
  • Bardejov, Slovakia
  • Levice, Slovakia
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Nov 2016, 7 months.

Results were first posted in Jul 2019, 2 years 7 months after primary completion.

Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 7 months is below that.

Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2016
First posted
May 4, 2016
StartActual
Apr 13, 2016
Primary completionActual
Nov 24, 2016
CompletionActual
Nov 24, 2016
Results first posted
Jul 12, 2019
Last update
Jul 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02761252
Responsible party
Sponsor
First posted
May 4, 2016
Start date
Apr 13, 2016
Primary completion
Nov 24, 2016
Completion
Nov 24, 2016
Results posted
Jul 12, 2019
Last update
Jul 12, 2019

Study contacts

Massimo Pistolesi, Prof
study director · AOUC Azienda Ospedaliero-Universitaria Careggi
Oliviero Rossi, Prof
study director · AOUC Azienda Ospedaliero-Universitaria Careggi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bilastine · Montelukast

Start the discussion